GS Investments Inc. Lowers Stock Holdings in Stryker Corporation $SYK

GS Investments Inc. lowered its position in shares of Stryker Corporation (NYSE:SYK) by 1.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,012 shares of the medical technology company’s stock after selling 226 shares during the period. Stryker comprises about 2.6% of GS Investments Inc.’s holdings, making the stock its 11th largest holding. GS Investments Inc.’s holdings in Stryker were worth $5,939,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SYK. Nuveen LLC purchased a new position in shares of Stryker during the 1st quarter valued at about $558,075,000. Price T Rowe Associates Inc. MD boosted its stake in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. grew its position in Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after acquiring an additional 549,643 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after acquiring an additional 361,136 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after acquiring an additional 261,058 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Price Performance

SYK stock opened at $355.74 on Friday. The stock has a market capitalization of $136.04 billion, a price-to-earnings ratio of 47.12, a PEG ratio of 2.66 and a beta of 0.94. The firm’s 50-day moving average price is $374.63 and its two-hundred day moving average price is $381.22. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period last year, the firm earned $2.87 earnings per share. Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 520,500 shares of company stock worth $184,803,065. Corporate insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research reports. Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. BTIG Research raised their price objective on Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Evercore ISI lowered their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Finally, Needham & Company LLC increased their target price on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $433.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.